Potential use of Immunodaat (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study
Deshpande, S.; Mundhe, N.; Deshpande, V.; Tamoli, S.; Mahadik, S.; Pawar, V.
Show abstract
BackgroundImmunodaat, a proprietary botanical extract, contains standardized extract of Elderberry (Sambucus Nigra L.). Elderberry is used as an immunity enhancer for prevention and management of various respiratory diseases and as an anti-oxidant. ObjectivesThe present study evaluated the effect of Immunodaat, in Post Covid-19 recovery. MethodsAn open labeled, comparative, randomized, multi-centric, prospective clinical study was conducted on 74 subjects who had post COVID-19 symptoms recovery from mild-moderate COVID-19 within the last 15 days. Subjects were divided equally, with 37 subjects in trial and control groups each, where subjects in trial group were given Immunodaat capsules in a dose of 250 mg Capsules twice daily along with the standard care for COVID-19 for consecutive 30 days while subjects in control group were given only the standard care for Post Covid. Subjects were evaluated for post clinical recovery signs and symptoms (like cough, fatigue, Myalgia, Joint pain, confusion, altered mood, anxiety, insomnia etc.) and lab parameters. Subjects were evaluated for quality of life using WHO QOL BREF. ResultsContinuous 30 days administration of Immunodaat showed a significant difference in reducing physical as well as mental symptoms when compared to the control group. Also, a significant improvement in quality of life was observed on WHO QOL BREF scale with the use of Immunodaat compared to the control group. Overall quality of life, energy levels and stamina levels improved with the use of Immunodaat. Subjects showed excellent tolerability and did not have any adverse effect with the use of Immunodaat. ConclusionThe study concludes that use of Immunodaat over 30 days aided to normalize the physical and mental symptoms that occurred due to Post COVID and long COVID. Immunodaat can be considered as a safe and effective natural ingredient in the management of Post COVID-19 or long COVID condition.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combinatorial effects of Zingiber officinale and Citrus limon juices: Hypolipidemic and antioxidant insights from in vivo, in vitro, and in silico investigations 97%
- Efficacy and safety of Mojeaga remedy in combination with conventional oral iron therapy for correcting anemia in obstetric population: a phase II randomized pilot clinical trial 97%
- Antioxidant enriched fraction from Pueraria tuberosa alleviates ovariectomized-induced osteoporosis in rats, and inhibits growth of breast and ovarian cancer cell lines in vitro 96%
Similar papers in this journal
- The PBL teaching method in Neurology Education in the Traditional Chinese Medicine undergraduate students: An Observational Study 93%
- Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India 92%
- Relationship between Serum Leptin, Lipid Metabolism, HbA1c, and Renal Function in Individuals with Type 2 Diabetes Mellitus and Obesity and in Individuals with Type 2 Diabetes Mellitus without Obesity 91%
Similar papers in this journal
- A Randomized, Double-Blind, Placebo Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN™ for Improving Sleep 94%
- Effects of cannabidiol on activated immune-inflammatory pathways in major depressive patients and healthy controls 93%
- Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma 90%
Similar papers in this journal
- A Novel Maxillofacial Technology for Drug Administration-A Randomized Controlled Trial Using Metronidazole. 96%
- Clearing the fog: Is Hydroxychloroquine effective in reducing Corona virus disease-2019 progression: A randomized controlled trial 95%
- Comparative study between first and second wave of COVID-19 deaths in India - a single center study 94%
Similar papers in this journal
- Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine – A Study Protocol 96%
- Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial 96%
- Modified Preparation Method of Ideal Platelet-Rich Fibrin Matrix (PRFM) from Whole Blood 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.